Navigation Links
Studies in Biological Technology

Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading

SCOTTSDALE, Ariz., Aug. 7 /PRNewswire/ -- Two studies released August 6, 2009 in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat some painful spine fractures, is not effective. According to several authorities in the field, this is in...

GeoVax Labs, Inc. Provides Clinical Studies Update

ATLANTA, Aug. 5 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based HIV/AIDS vaccine development company, today announced updates on its ongoing and planned human clinical trials. "We have two main areas of focus for our HIV/AIDS vaccine - ...

Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine

Trivalent Virus-Like Particle Vaccine Elicits Protective Immune Responses against a Variety of Seasonal Influenza Strains in Mice and Ferrets ROCKVILLE, Md., June 24 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today publication of the preclinical study results that...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the ...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Socie...

Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)

Studies to be presented on safety and efficacy of SpyGlass System for diagnostic and therapeutic procedures throughout pancreatico-biliary system NATICK, Mass., May 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that 14 abstracts and additional clini...

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressiv...

Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple s...

Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies') Conference

PORTOLA VALLEY, Calif., May 19 /PRNewswire/ -- Spectros announced today that its T-Stat Tissue Oximeter was featured in two presentations at the Pediatric Academic Societies' (PAS) annual conference held in Baltimore, Maryland, May 2-5, 2009. The studies focused on clinical applications of the Sp...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) will unveil data from more than 50 studies at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. from May 29 to June 2, 2009, with the majority of the presentations continu...

Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray

GENEVA, Switzerland, March 31 /PRNewswire/ -- Viroblock SA has announced today that the first generation of VCCD Tech antiviral nasal spray formulation is active against human influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology (VCCD Tech) inactivates enveloped viruses d...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

Results of five clinical studies evaluating the predictive value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual Scientific Sessions of the American College of Cardiology in Orlando, Florida. The studies, amazingly, show that a simple, inexpensive te...

Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain

SAN FRANCISCO, Feb. 25 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled its first subjects in its once-daily topical diclofenac sodium patch Phase III program. The program consists of three randomized, double-blind, placebo-controlled Phase III clinical st...

FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers

NERVIANO, Italy, February 10 /PRNewswire/ -- - Nerviano Medical Sciences (NMS): Green Light From the FDA for the CDC7 Inhibitor Nerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct for the first time clinical trials of a novel antitum...

Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates

CAMBRIDGE, Mass., Feb. 3 /PRNewswire/ -- Abt Associates announced that Ricky Takai, Ph.D., has joined the company as Principal Associate. After a brief orientation to the firm, Dr. Takai will become the leader of the company's education work in September 2009. Dr. Takai brings his more than 20 y...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

- CAPACITY 2 Meets Primary and Key Secondary Endpoints - - CAPACITY 1 Misses Primary Endpoint, Provides Supportive Data - - Company Preparing to Submit NDA and MAA - BRISBANE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced results from the...

Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies

Training Physician for both Botox and Fraxel Repair, Nissan Pilest Board Certified Dermatologist in Orange County begins in-office clinical procedure studies to track the effectiveness of using Botox as a pre-treatment to enhance the improvements of fractional CO2 skin resurfacing. Specific to th...

BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)

Additional Safety Data Could Drive Product Adoption in High-Growth Cell Therapy Market BOTHELL, Wash., Dec. 16 /PRNewswire-FirstCall/ --BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media p...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with ...

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

ATLANTA, Dec. 8 /PRNewswire/ -- UCB today announced new findings from analyses of pooled Vimpat(R) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of treatment and across doses in a challenging patient population, when admi...

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Cente...

Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film

On Track to File NDA with FDA in Early to Mid-2009 WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that its development partner, MonoSol Rx, reported the...

BioInformatics, LLC Studies Effective Strategies for Scientific Publishing in a Web 2.0 World

ARLINGTON, Va., Dec. 1 /PRNewswire/ -- BioInformatics, LLC ( http://www.gene2drug.com ) -- the leading market research and consulting firm serving the life science industry -- announces the publication of its latest report, "The Brave New World of Scientific Publishing." Going beyond the original ...

Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis

SEATTLE, Oct. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced positive data from a Phase 1/2a study demonstrating that repeat administration with TRU-015 continues to produce persistent responses and significant improvements in rheumatoid arthritis (R...

New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence

Masimo's Commercial Exhibit Draws More Than 2,500 Conference Attendees IRVINE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that 13 new independent and objective clinical st...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

- Phase III data highlight the benefits of ACTEMRA for rheumatoid arthritis - NUTLEY, N.J., Oct. 20 /PRNewswire/ -- Roche today announced that a total of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment ACTEMRA(R) (tocilizumab) have been accepted for presentatio...

Five New Clinical Studies Show Value of Masimo PVI & PI

Data to be presented at American Society of Anesthesiologists Annual Meeting as Masimo showcases world's first-and-only noninvasive and continuous hemoglobin (SpHb) and Oxygen Content (SpOC) monitor with live booth demonstrations IRVINE, Calif., Oct. 17 /PRNewswi...

NIST studies how new helium ion microscope measures up

Just as test pilots push planes to explore their limits, researchers at the National Institute of Standards and Technology (NIST) are probing the newest microscope technology to further improve measurement accuracy at the nanoscale. Better nanoscale measurements are critical for setting standards ...

Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools

CHAPEL HILL, N.C., Aug. 22 /PRNewswire/ -- Quality and process improvement efforts gained new momentum over the past year in light of demands for higher efficiencies fueled by a stagnating economy. Biopharmaceutical companies are facing quality issues on multiple fronts -- smaller pipelines ar...

Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)

- Company to Host Conference Call to Update Clinical Program - CALGARY, July 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has now enrolled and treated 200 cancer patients in clinical studies with REOLYSIN(R), its proprietar...

Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis

PARIS, France - 11 June 2008 Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) experienced significant improvements in the signs and symptoms of rheumatoid arthritis (...

Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma

CHICAGO, June 2 /PRNewswire-FirstCall/ -- At the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), two studies were presented investigating the potential utility of Zevalin(R) (Ibritumomab Tiuxetan) radioimmunotherapy as replacement for external beam radiations or supple...

DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance

BOSTON, May 21 /PRNewswire/ -- DolmatConnell and Partners released our 2008 studies of executive compensation in the Tech100 and LifeScience100 (the studies are available for download at ( http://www.dolmatconnell.com ) today and issued the below press release that we wanted to ensure that you...

Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infections

- Two New Studies Provide Further Evidence that PS Plays a Critical Role in Some Viral Infections - - Peregrine's Anti-PS Antibody Bavituximab is Currently Being Assessed in a Clinical Trial in HCV Patients Co-Infected with HIV - TUSTIN, Calif., May 13 /PRNewswire-...

Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution

MUNDELEIN, Ill., April 22 /PRNewswire/ -- Sysmex America, Inc. today announced the successful completion of Mercy Medical Center's (Canton, OH) beta studies for its integrated hematology and A1C automation solution. This first-of-kind solution, which combines the Sysmex HST-N hematology automa...

AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)

WILMINGTON, Del., March 12 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cel...

PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008

ANNAPOLIS, Md., March 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has completed the initial pharmacokinetic (PK) testing of ...

Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)

BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the global specialty biopharmaceutical company, notes that Renovo Group plc, (LSE: RNVO) ("Renovo") has today announced the results of Renovo's latest Phase 2 studies ...

NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, usin...

BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market

ARLINGTON, Va., Feb. 28 /PRNewswire/ -- BioInformatics, LLC ( http://www.gene2drug.com ) -- the leading market research and consulting firm serving the life science industry -- announces the publication of its latest report, "Conferences & Exhibits in the Life Sciences: What's Working Now." Ex...
Other Tags
(Date:4/23/2014)... analysis of NASA satellite data shows Africa,s Congo rainforest, ... a large-scale decline in greenness over the past decade. ... at Albany, State University of New York, shows between ... of forest area and intensified. The research, published Wednesday ... comprehensive observational studies to explore the effects of long-term ...
(Date:4/23/2014)... Burning coal for domestic heating may contribute to early ... from The Saban Research Institute of Children,s Hospital Los ... in the world. , In a paper published today ... researchers report ,"alarmingly strong statistical correlations" between seasonal ambient ... , UB has one of the highest levels ...
(Date:4/23/2014)... -- Like a hungry diner ripping open a dinner ... electricity must tear open a hydrogen molecule. Now researchers ... onto the two halves of its hydrogen feast. The ... to make the catalyst work better for alternative energy ... have shown precisely where the hydrogen halves end up ...
Breaking Biology News(10 mins):NASA satellites show drought may take toll on Congo rainforest 2NASA satellites show drought may take toll on Congo rainforest 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4
(Date:4/24/2014)... with the negative and stressful outcomes for parents who ... a life-limiting illness, says a recent study led by ... the challenges are numerous and life-changing and stress levels ... the Waterloo-led research reported positive outcomes as well, a ... the most recent issue of the American Journal ...
(Date:4/24/2014)... Changes in managing patients before, during and after colorectal ... readmission rates, according to researchers who led a study ... practice, called enhanced recovery, is easier on patients before ... evacuation that are typically prescribed. After surgery, patients are ... possible, leading to faster recoveries. , Among findings published ...
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
(Date:4/24/2014)... affects more than one out of three survivors ... released in The Lancet Respiratory Medicine , ... physically rather than mentally. , It is one ... health and functional outcomes of critical care survivors, ... professor of Medicine, and it highlights a significant ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Boring cells could hold the key to heart disease 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
Other Contents